Table 11.
Group | G6Pase | GK activity | Glycogen (mg/g) | HK activity | |
---|---|---|---|---|---|
activity (mU) | (mU) | Liver | Skeletal muscle | (U/mg protein) | |
Normal control | 0.40 ± 0.006 | 3.38 ± 0.05 | 19.64 ± 2.45 | 11.74 ± 4.39 | 1.69 ± 0.07 |
SD control | 0.71 ± 0.005a | 1.36 ± 0.06a | 9.67 ± 3.12a | 4.89 ± 1.34a | 1.31 ± 0.03a |
MD control | 0.69 ± 0.002a | 1.27 ± 0.08a | 10.23 ± 4.35a | 5.27 ± 1.56a | 1.29 ± 0.05a |
SD + AL-H | 0.53 ± 0.008ab | 2.8 ± 0.04ab | d17.53 ± 5.18b | d9.78 ± 1.54b | d1.53 ± 0.09ab |
MD + AL-H | 0.46 ± 0.007ab | 3.09 ± 0.03ab | d18.13 ± 5.80b | d10.89 ± 2.41b | d1.59 ± 0.05ab |
GB 4 (mg/kg) | 0.39 ± 0.004b | 3.11 ± 0.04b | 17.78 ± 2.30b | 11.01 ± 1.96b | 1.60 ± 0.03ab |
Each value represents mean ± SD, (n = 10); ANOVA followed by multiple two-tail “t” test. In each vertical column, mean with different superscripts (a, b) differed from each other. Significant difference of diabetic control from normal control a P < 0.001. Significant difference of treated groups from diabetic control b P < 0.01, c P < 0.05, d P < 0.01 when compared with glibenclamide 4 mg/kg treated group.